Bristol-Myers Squibb Co (BMY) Shares Sold by Novare Capital Management LLC

Novare Capital Management LLC trimmed its position in Bristol-Myers Squibb Co (NYSE:BMY) by 3.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,224 shares of the biopharmaceutical company’s stock after selling 1,555 shares during the period. Novare Capital Management LLC’s holdings in Bristol-Myers Squibb were worth $2,342,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of BMY. Delphi Private Advisors LLC bought a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $108,000. Atlantic Trust LLC bought a new stake in Bristol-Myers Squibb during the 2nd quarter worth approximately $111,000. Massey Quick Simon & CO. LLC increased its holdings in Bristol-Myers Squibb by 523.5% during the 3rd quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after purchasing an additional 1,492 shares in the last quarter. Horan Capital Advisors LLC. bought a new stake in Bristol-Myers Squibb during the 3rd quarter worth approximately $122,000. Finally, Acrospire Investment Management LLC increased its holdings in Bristol-Myers Squibb by 633.3% during the 2nd quarter. Acrospire Investment Management LLC now owns 2,200 shares of the biopharmaceutical company’s stock worth $123,000 after purchasing an additional 1,900 shares in the last quarter. 71.55% of the stock is owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

In other Bristol-Myers Squibb news, Director Theodore R. Samuels II bought 4,000 shares of the business’s stock in a transaction dated Friday, December 15th. The shares were purchased at an average price of $62.30 per share, for a total transaction of $249,200.00. Following the purchase, the director now directly owns 22,000 shares of the company’s stock, valued at $1,370,600. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. 0.23% of the stock is owned by insiders.

Bristol-Myers Squibb Co (BMY) opened at $67.45 on Tuesday. Bristol-Myers Squibb Co has a 12 month low of $51.56 and a 12 month high of $70.05. The firm has a market capitalization of $110,885.03, a P/E ratio of 22.57, a PEG ratio of 2.08 and a beta of 0.98. The company has a quick ratio of 1.43, a current ratio of 1.55 and a debt-to-equity ratio of 0.59.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.01. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The firm had revenue of $5.45 billion for the quarter, compared to the consensus estimate of $5.35 billion. During the same quarter in the previous year, the business earned $0.63 EPS. The company’s revenue was up 3.9% compared to the same quarter last year. research analysts forecast that Bristol-Myers Squibb Co will post 3.21 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, May 1st. Stockholders of record on Friday, April 6th will be paid a $0.40 dividend. The ex-dividend date is Thursday, April 5th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.37%. Bristol-Myers Squibb’s payout ratio is presently 271.19%.

A number of analysts have commented on the company. Vetr lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $59.70 price objective for the company. in a report on Friday, December 22nd. BMO Capital Markets set a $51.00 price objective on Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Wednesday, February 14th. Zacks Investment Research lowered Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Monday, January 29th. TheStreet lowered Bristol-Myers Squibb from a “b” rating to a “c+” rating in a report on Thursday, March 8th. Finally, Credit Suisse Group set a $62.00 price objective on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Monday, January 22nd. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $66.30.

COPYRIGHT VIOLATION NOTICE: “Bristol-Myers Squibb Co (BMY) Shares Sold by Novare Capital Management LLC” was first posted by Markets Daily and is owned by of Markets Daily. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.themarketsdaily.com/2018/03/13/bristol-myers-squibb-co-bmy-shares-sold-by-novare-capital-management-llc.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply